{"name": "Tetraphase Pharmaceuticals",
 "permalink": "tetraphase-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/tetraphase-pharmaceuticals",
 "homepage_url": "http://tphase.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": null,
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "",
 "description": "",
 "created_at": "Thu Jan 01 05:08:32 UTC 2009",
 "updated_at": "Thu Jan 26 03:14:47 UTC 2012",
 "overview": "\u003Cp\u003ECapitalizing on breakthrough synthetic chemistry, Tetraphase Pharmaceuticals is leveraging a dynamic drug engine targeted at several significant disease categories.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       25],
      "assets/images/resized/0003/2808/32808v1-max-150x150.png"],
     [[250,
       41],
      "assets/images/resized/0003/2808/32808v1-max-250x250.png"],
     [[251,
       42],
      "assets/images/resized/0003/2808/32808v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$60M",
 "funding_rounds":
  [{"round_code": "a",
    "source_url": "http://www.equityhelpdesk.com/PrivateEquity/Tetraphase_Adds_15_Million",
    "source_description": "Equity Help Desk",
    "raised_amount": 15000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2008,
    "funded_month": 8,
    "funded_day": 7,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Mediphase Venture Partners",
         "permalink": "mediphase-venture-partners",
         "image":
          {"available_sizes":
            [[[150,
               77],
              "assets/images/resized/0003/2809/32809v1-max-150x150.png"],
             [[170,
               88],
              "assets/images/resized/0003/2809/32809v1-max-250x250.png"],
             [[170,
               88],
              "assets/images/resized/0003/2809/32809v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "CMEA Ventures",
         "permalink": "cmea-ventures",
         "image":
          {"available_sizes":
            [[[125,
               47],
              "assets/images/resized/0002/3432/23432v2-max-150x150.jpg"],
             [[125,
               47],
              "assets/images/resized/0002/3432/23432v2-max-250x250.jpg"],
             [[125,
               47],
              "assets/images/resized/0002/3432/23432v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Fidelity Ventures",
         "permalink": "fidelity-ventures",
         "image":
          {"available_sizes":
            [[[150,
               38],
              "assets/images/resized/0001/0980/10980v1-max-150x150.jpg"],
             [[218,
               56],
              "assets/images/resized/0001/0980/10980v1-max-250x250.jpg"],
             [[218,
               56],
              "assets/images/resized/0001/0980/10980v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Flagship Ventures",
         "permalink": "flagship-ventures",
         "image":
          {"available_sizes":
            [[[150,
               34],
              "assets/images/resized/0002/8188/28188v4-max-150x150.png"],
             [[250,
               57],
              "assets/images/resized/0002/8188/28188v4-max-250x250.png"],
             [[323,
               74],
              "assets/images/resized/0002/8188/28188v4-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Skyline Ventures",
         "permalink": "skyline-ventures",
         "image":
          {"available_sizes":
            [[[150,
               53],
              "assets/images/resized/0025/1697/251697v1-max-150x150.png"],
             [[250,
               88],
              "assets/images/resized/0025/1697/251697v1-max-250x250.png"],
             [[300,
               106],
              "assets/images/resized/0025/1697/251697v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "c",
    "source_url": "http://www.fiercebiotech.com/story/tetraphase-hauls-45m-c-round-back-antibiotic-work/2010-06-01?utm_medium=rss\u0026utm_source=rss",
    "source_description": "Tetraphase hauls in $45M C round to back antibiotic work",
    "raised_amount": 45000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 6,
    "funded_day": 1,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Excel Medical Ventures",
         "permalink": "excel-medical-fund",
         "image":
          {"available_sizes":
            [[[150,
               20],
              "assets/images/resized/0004/8807/48807v1-max-150x150.jpg"],
             [[250,
               33],
              "assets/images/resized/0004/8807/48807v1-max-250x250.jpg"],
             [[386,
               52],
              "assets/images/resized/0004/8807/48807v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "CMEA Ventures",
         "permalink": "cmea-ventures",
         "image":
          {"available_sizes":
            [[[125,
               47],
              "assets/images/resized/0002/3432/23432v2-max-150x150.jpg"],
             [[125,
               47],
              "assets/images/resized/0002/3432/23432v2-max-250x250.jpg"],
             [[125,
               47],
              "assets/images/resized/0002/3432/23432v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Fidelity Biosciences",
         "permalink": "fidelity-biosciences-2",
         "image":
          {"available_sizes":
            [[[150,
               50],
              "assets/images/resized/0005/0044/50044v1-max-150x150.png"],
             [[233,
               79],
              "assets/images/resized/0005/0044/50044v1-max-250x250.png"],
             [[233,
               79],
              "assets/images/resized/0005/0044/50044v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Flagship Ventures",
         "permalink": "flagship-ventures",
         "image":
          {"available_sizes":
            [[[150,
               34],
              "assets/images/resized/0002/8188/28188v4-max-150x150.png"],
             [[250,
               57],
              "assets/images/resized/0002/8188/28188v4-max-250x250.png"],
             [[323,
               74],
              "assets/images/resized/0002/8188/28188v4-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Mediphase Venture Partners",
         "permalink": "mediphase-venture-partners",
         "image":
          {"available_sizes":
            [[[150,
               77],
              "assets/images/resized/0003/2809/32809v1-max-150x150.png"],
             [[170,
               88],
              "assets/images/resized/0003/2809/32809v1-max-250x250.png"],
             [[170,
               88],
              "assets/images/resized/0003/2809/32809v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Skyline Ventures",
         "permalink": "skyline-ventures",
         "image":
          {"available_sizes":
            [[[150,
               53],
              "assets/images/resized/0025/1697/251697v1-max-150x150.png"],
             [[250,
               88],
              "assets/images/resized/0025/1697/251697v1-max-250x250.png"],
             [[300,
               106],
              "assets/images/resized/0025/1697/251697v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "480 Arsenal Street,",
    "address2": "Suite 110",
    "zip_code": "02472",
    "city": "Watertown",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": 42.3630235,
    "longitude": -71.158939}],
 "milestones":
  [{"description": "appointed a new member to its board of directors",
    "stoned_year": 2010,
    "stoned_month": 10,
    "stoned_day": 13,
    "source_url": "http://www.masshightech.com/stories/2010/10/11/daily91-Tetraphase-appoints-former-Sirtris-exec-Bohlin-to-board.html",
    "source_text": null,
    "source_description": "Tetraphase appoints former Sirtris exec Bohlin to board",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Tetraphase Pharmaceuticals",
      "permalink": "tetraphase-pharmaceuticals"}},
   {"description": "has named Patrick Horn, formerly of Dyax Corp., as the company\u00e2\u20ac\u2122s first chief medical officer",
    "stoned_year": 2011,
    "stoned_month": 1,
    "stoned_day": 24,
    "source_url": "http://www.masshightech.com/stories/2011/01/24/daily10-Horn-named-chief-medical-officer-at-Tetraphase.html",
    "source_text": null,
    "source_description": "Horn named chief medical officer at Tetraphase",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Tetraphase Pharmaceuticals",
      "permalink": "tetraphase-pharmaceuticals"}},
   {"description": "NIAID biothreat contract could bring $36M to Tetraphase",
    "stoned_year": 2011,
    "stoned_month": 10,
    "stoned_day": 19,
    "source_url": "http://www.masshightech.com/stories/2011/10/17/daily38-NIAID-biothreat-contract-could-bring-36M-to-Tetraphase.html",
    "source_text": "",
    "source_description": "NIAID biothreat contract could bring $36M to Tetraphase",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Tetraphase Pharmaceuticals",
      "permalink": "tetraphase-pharmaceuticals"}},
   {"description": "BARDA biothreat contract could bring $40M to Tetraphase",
    "stoned_year": 2012,
    "stoned_month": 1,
    "stoned_day": 25,
    "source_url": "http://www.masshightech.com/stories/2012/01/23/daily32-BARDA-biothreat-contract-could-bring-40M-to-Tetraphase.html",
    "source_text": "",
    "source_description": "BARDA biothreat contract could bring $40M to Tetraphase",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Tetraphase Pharmaceuticals",
      "permalink": "tetraphase-pharmaceuticals"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}